SCHEMBL3581276

SCHEMBL3581276

COc1cccc2c1C(N)CC(C)(C)O2

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.35
CTSD P07339 1/20 0.34
BACE1 P56817 1/20 0.34
AADAT Q8N5Z0 2/20 0.34
DRD2 P14416 1/20 0.34
DRD3 P35462 1/20 0.34
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.33
CYP3A4 P08684 1/20 0.33
GAA P10253 1/20 0.33
CYP2C19 P33261 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MAOA P21397 1/20 0.33
ADRA1A P35348 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3409136 0.81 TRPV3 (0.38) AADATDRD2DRD3HTR2AHTR2C
SCHEMBL20480671 0.79 CYP3A4 (0.37) ALDH1A1CYP3A4GAACYP2C19L3MBTL1
SCHEMBL10602416 0.78 MEN1 (0.46) ALDH1A1HTR2CCYP3A4GAAKDM4E
SCHEMBL3596638 0.76 ALDH1A1 (0.49) ALDH1A1DRD2DRD3HTR2AHTR2C
SCHEMBL23423105 0.75 KMT2A (0.42) ALDH1A1HTR2CCYP3A4GAACYP2C19
SCHEMBL1922464 0.74 HTR1A (0.44) ALDH1A1DRD2HTR2AHTR2CCYP3A4
SCHEMBL2240288 0.74 HTR1A (0.44) ALDH1A1DRD2HTR2AHTR2CCYP3A4
SCHEMBL1237664 0.74 TRPV1 (0.37)
SCHEMBL29654106 0.74 TRPV1 (0.37)
SCHEMBL22997112 0.74 TRPV1 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7662811-B2 N-(((5R)-5-((1-methylethyl)amino)-5,6,7,8-tetrahydro-2-naphthalenyl)methyl)-2-((2R)-1-((4-methylphenyl)sulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-pyrazinyl)acetamide; for treatment of pain and diseases, such as inflammation mediated diseases AMGEN INC. (US) 2010-02-16 US disclosed
US-20060025400-A1 1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use AMGEN INC. 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025400-A1 1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use AADAC, PTGES2, LTC4S ALDH1A1 158/4885CTSD 1918/4885BACE1 1398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.